Back
8-K ↗8-K ↗
IMVT
Immunovant, Inc.
Immunovant develops immunology-focused drug candidates using a monoclonal antibody approach, with IMVT-1402 and batoclimab (formerly IMVT-1401) as its primary product candidates in clinical development. The company is in the clinical trial stage, working toward regulatory approval and eventual commercialization of these product candidates across multiple therapeutic indications.
$27.14+68.08%1Y
IMVT · daily close · illustrative · 0 catalysts marked
Pipeline
UnknownIndication pending review
UnknownIndication pending review
Catalyst Calendar
H1
Readoutbatoclimab
“We continue to expect the first of the two batoclimab Phase 3 TED studies to read out before the end of calendar year 2025. However, due to evolving competitive dynamics, we anticipate sharing top-line results from both TED studies concurrently in the first half of calendar year 2026.”
2027
ReadoutIMVT-1402
“we continue to expect to meet our previously disclosed anticipated milestones, including for the two potentially registrational trials evaluating IMVT-1402 in adults with Graves' Disease, for which we expect to report top-line results in 2027.”